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Abstract
Aim The purpose of this pilot study was to assess whether renal sympathetic denervation (RDN) decreases atrial fibrillation 
(AF) burden in hypertensive patients with symptomatic AF at 6- and 12-month follow-up, as measured using an implantable 
cardiac monitor (ICM).
Methods and results A total of 20 patients with symptomatic paroxysmal or persistent AF (EHRA ≥ II) and primary hyperten-
sion with a mean office systolic blood pressure (BP) of > 140 mmHg were enrolled. After enrolment, an ICM was implanted 
3 months pre-RDN to monitor AF burden. Quality of life (QOL) was assessed using the Atrial Fibrillation Effect on QualiTy-
of-life (AFEQT) questionnaire. Mean age was 64 ± 7 years and 55% were females. AF burden in min/day decreased from a 
median (IQR) of 1.39 (0–11) pre-RDN to 0.67 (0–31.6) at 6 months (p = 0.64) and to 0.94 (0–6.0) at 12 months (pre-RDN vs. 
12 months; p = 0.03). QOL improved significantly at both 6 months (+ 11 ± 15 points, p = 0.006) and 12 months (+ 10 ± 19, 
p = 0.04) as compared to pre-RDN. Office BP decreased significantly at 12-month follow-up (− 20 ± 19/− 7 ± 10 mmHg), 
p < 0.01) as compared to pre-RDN. Ambulatory BP decreased − 7 ± 16/− 3 ± 9 mmHg (p > 0.05) at 12-month follow-up as 
compared to pre-RDN.
Conclusion This pilot study suggests that RDN might be able to decrease AF burden in min/day as measured using an ICM, 
with a positive effect on QOL. Large-scale randomized trials are needed to prove the definite value of RDN in hypertensive 
patients with atrial fibrillation.
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Introduction
AF is the most common arrhythmia worldwide, occurring in 
2–3% of the adult population [1]. The incidence of AF, along 
with an inherent risk for thromboembolic events, increases 
with age and the presence of hypertension [2]. Vice versa, 
hypertension is the most common cardiovascular condition 
responsible for the development and recurrence of AF [3]. 
AF is associated with an impaired quality of life (QOL) and 
is known to increase the risk of hospitalization by two- to 
threefold resulting in increased health care costs [4]. In gen-
eral, the current treatment options for AF can be divided into 
either pharmacological and/or ablation therapy (i.e. pulmo-
nary vein isolation, PVI), performed either by percutaneous 
or surgical techniques. Despite improving tools and tech-
niques, many patients remain symptomatic and side effects 
of pharmacological treatment are common with high recur-
rence rates following catheter ablation, especially in patients 
with hypertension [5–7]. Furthermore, major complications 
as tamponade and stroke have been reported in up to 4.5% 
of the patients treated with percutaneous techniques, while 
the impact on survival associated with any of the therapies 
mentioned above is still disputed [8]. Previous pathophysi-
ological studies described a correlation of AF burden to 
hyperactivity of the sympathetic nervous system (SNS) 
and demonstrated that, by modulating the SNS directly, 
AF control might improve significantly [9–11]. While renal 
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sympathetic denervation (RDN) has been studied to help 
control hypertension [12], its potential value in improving 
signs and symptoms of AF is currently unknown. The aim of 
the present pilot study was to assess if RDN decreases occur-
rence and symptoms of AF in patients with symptomatic 
paroxysmal or persistent AF at 6- and 12-month follow-up.
Methods
Study design and patient population
This study is a single-arm pilot study including 20 patients. 
Patients were eligible for enrolment if all of the following 
inclusion criteria were met: paroxysmal or persistent AF, 
hypertension (mean office systolic BP ≥ 140 mmHg), use of 
≥ 2 antihypertensive drugs, age ≥ 18 years, estimated glo-
merular filtration rate (eGFR) > 45 ml/min/1.73 m2. Parox-
ysmal AF was defined as an episode of AF that terminated 
spontaneously in less than 7 days. Persistent AF was defined 
as AF that fails to terminate in 7 days and an intervention 
was needed to restore sinus rhythm (pharmacologic or elec-
trical cardioversion).
Patients with permanent AF, renal artery abnormalities, 
first episode of AF, comorbidities with a life expectancy of 
less than 1 year or unwillingness to undergo RDN or ICM 
implantation or follow-up visits were excluded. Secondary 
causes for hypertension were excluded prior to enrolment. 
The study was approved by our local ethics committee and 
all patients provided written informed consent (trialregister.
nl, NTR number: NTR5329).
Study measurements and endpoints
Clinical and laboratory data were obtained at 1, 3, 6 and 
12 months post-RDN; annual follow-up will be continued up 
to 3 years. The primary efficacy objective, AF burden, was 
measured with the SJM Confirm DM2102 ICM (St. Jude 
Medical, St Paul, MN, USA) featuring both an automatic 
and a manual activation trigger, AF triggers, heart rate histo-
grams, mean heart rate and ventricular rate response (VRR) 
monitoring during AF. The primary safety objective was 
defined as a composite of death from cardiovascular causes, 
stroke, major access site bleeding, acute kidney injury or 
renal artery stenosis.
Serious adverse events (SAE’s) and adverse events 
reported spontaneously by the subject or observed at each 
follow-up or any time in between, were recorded by the 
investigator. A SAE was defined as follows: any untoward 
medical occurrence, or effect, which in any dose results in 
events that were fatal or life-threatening, or that required a 
prolonged hospitalization; as well as any other important 
medical event that required intervention.
Secondary outcomes included change in office BP, ambu-
latory blood pressure measurements (ABPM), change in 
24 h-holter monitoring, change in echocardiographic param-
eters (change in left ventricular (LV) and left atrial (LA) vol-
umes and dimensions and change in LV diastolic function) 
and QOL measurements (using the AFEQT questionnaire). 
The AFEQT questionnaire is an AF-specific health related 
QOL questionnaire designed to be used in different clinical 
settings and for research purposes to assess the impact of 
AF on patients QOL. Overall or subscale scores range from 
0 (complete disability or limitations) to 100 (no disability 
or limitations) [13].
Office BP was measured at each follow-up visit with an 
automatic blood pressure monitor (Omron M10-IT). ABPM 
was performed using the Ultralite Ambulatory Blood Pres-
sure monitor (Spacelabs Healthcare, model 90217A) and 
24 h-holter monitoring was performed with the evo digital 
recorder (Del Mar Reynolds, Spacelabs Healthcare) to assess 
changes in (supra) ventricular ectopic beats (S)VE beats.
We aimed to maintain the antihypertensive and antiar-
rhythmic drug regimen during the course of the study in all 
patients; however, changes were allowed in case of hypoten-
sion, hypertension or frequent AF episodes.
ICM implantation and interrogation
ICM [SJM Confirm DM2102 (St. Jude Medical, St Paul, 
MN, USA)] implantation was performed by an electrophysi-
ologist under local anesthesia 3 months pre RDN. A small 
incision (about 2–3 cm) was made lateral to the sternum at 
the level of the fourth and the fifth intercostal spaces. After 
the procedure, patients were instructed to use the activator 
in case of symptoms. To measure AF burden, the ICM was 
interrogated at each study visit per protocol by an expert 
(DT) to obtain the following parameters: functional status 
of the device, device battery level, analysis of any abnormal 
heart rhythms (AF, tachycardia, bradycardia and asystole) 
along with the highest VRR during AF episodes.
Final AF burden was assessed by confirming the AF 
episodes on the ECG readings to prevent false positive and 
false negative results. The minimum arrhythmia duration 
for an appropriate AF episode to be recorded was 30 s and 
a tachycardia cut-off rate of 120 bpm was applied. Final 
outcomes were based on 3-month intervals; pre-RDN (0–3 
months pre- procedure), 6 months (3–6 months post-RDN) 
and 12 months (9–12 months post-RDN). AF burden was 
defined as the average minutes/day spent in AF. Prior to 
procedure a total of 2/20 patients with persistent AF pro-
gressed to permanent AF when using data derived from the 
long-term ECG recordings through ICM, both patients were 
excluded from the assessment of the primary outcome due 
to inequivalent burdens of AF as compared to patients with 
paroxysmal or persistent AF.
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RDN procedure
All patients were preloaded with 300 mg aspirin, if naïve, 
and advised to continue with aspirin for at least 1 month. 
Pre-procedurally, 100  IU heparin/kg was administered 
to achieve an active clotting time > 250 s. All procedures 
were performed under conscious sedation. After adminis-
tration of local anesthesia, common femoral artery access 
was achieved by an ultrasound-guided puncture and a 6-Fr 
sheath was then introduced. Under fluoroscopic guidance, 
the short 6-Fr sheath was exchanged for an 8-Fr RDN or an 
IMA-tipped guiding sheath, to accommodate the St. Jude 
EnligHTN™ system. After smoothly engaging the renal 
arteries by using a no-touch technique with the help of a 
standard high-torque BHW coronary guidewire, selective 
renal artery angiograms were made and an appropriate bas-
ket size was chosen (small basket 4.0–5.5 mm diameter/
large basket 5.5–8.0 mm diameter). The BHW guidewire 
was exchanged for the EnligHTN™ ablation catheter with its 
tip proximal to the bifurcation of the main renal artery. The 
basket catheter, containing four bipolar Platinum–Iridium 
electrodes, was then opened with the impedance of each 
electrode on the basket monitored. After a total of four abla-
tions were performed successfully the basket was collapsed 
and retracted proximally while another four ablations were 
performed in the same artery, with the intention to achieve 
at least eight successful ablations per artery.
Statistical analysis
Continuous variables were expressed as mean ± standard 
deviation (SD) when normally distributed; non-normally 
distributed variables were presented as median [interquar-
tile range, IQR]. Categorical variables were expressed as 
percentages. Continuous variables were using Student’s 
t test. Categorical variables were compared with the Chi 
square test or Fisher’s Exact test when appropriate. The Wil-
coxon signed-rank test or McNemar’s test were performed 
to analyse the AF burden. Spearman correlation coefficient 
was used to evaluate the relationship between blood pres-
sure drop and the change in AF burden. The Friedman test 
was performed to analyse EHRA class. All statistical tests 
are 2-tailed. A p value < 0.05 was considered statistically 
significant. Statistical analysis was performed using SPSS 
statistical analysis (version 21.0).
Results
Between July 2014 and February 2016 a total of 136 patients 
were screened for eligibility. Twenty patients (14.7%) met 
the inclusion criteria (Fig. 1). Baseline characteristics are 
presented in Table 1. In brief, nine patients were males and 
mean age was 64 ± 7 years. Mean office blood pressure 
was 153/88 mmHg. Most patients were on rhythm control 
(19/20) and 20% of the patients had a history of pulmonary 
vein isolation. Timing between the RDN- and the previous 
PVI-procedure in 4/20 patients was 916 ± 116 days. Based 
on ambulatory BP measurements a total of 11 patients had 
essential hypertension according the definitions of the Euro-
pean Society of Hypertension [14] and nine patients had 
white coat uncontrolled hypertension. None of the patients 
had a history of obstructive sleep apnea syndrome.
AF burden decreased at 6 and 12 months. AF burden 
(min/day) was 1.39 (0–10.9) pre-RDN vs. 0.67 (0–31.6) at 
6 months (p = 0.64) and 0.94 (0–6.0) at 12 months (p = 0.03). 
Changes in AF episodes and change in the total minutes in 
AF are presented in Table 2.
Two patients progressed from persistent AF to permanent 
AF prior to RDN and were excluded from AF burden analy-
sis. Both patients underwent failed attempts to restore sinus 
rhythm by ECV. Despite persistent EHRA class II on rate 
control both patients declined PVI during the course of the 
study.A sub analysis in patients with a history of PVI and an 
additional RDN showed a numerical decrease in AF burden 
min/day at 6 months and 1 year follow-up, from a median 
of 973 min (11.1–1440) to 12.9 min (3.7–22.8) at 6 months 
to 1.57 (0.5–27.3) at 1 year (p > 0.05 for both).
Renal function remained unchanged at both 6- and 
12-month follow-up, eGFR (ml/min) pre-RDN was 83 ± 20 
vs. 86 ± 21 at 6 months (p = 0.23) and 86 ± 23 at 12 months 
(p = 0.14). No cases of cardiovascular death, stroke, major 
access site bleeding, acute kidney injury or renal artery ste-
nosis were reported. One peri-procedural complication was 
reported involving a renal artery dissection that resolved 
after balloon dilatation.
Office systolic BP decreased from 153 ± 17 mmHg pre-
procedure to 148 ± 17 mmHg at 6 months (p = 0.13) and to 
133 ± 16 at 12-month follow-up (p < 0.01) (Table 3). No cor-
relation was found between Δ BP (ABPM) and Δ AF burden 
(in terms of min/day or episodes); at 12 months (Δ number 
of AF episodes and Δ mean 24 h systolic ABPM r = − 0.09; 
p = 0.74 and ΔAF min/day and Δ mean 24 h systolic ABPM, 
r = 0.30; p = 0.28).
Mean heart rate on 24 h-holter monitoring remained 
unchanged at 6- months (− 5 ± 14  bpm; p = 0.15) and 
12-month follow-up (− 1 ± 14 bpm; p = 0.63) as compared 
to baseline. A numerical decrease was seen in SVE beats at 
6- and 12-month follow-up as compared to pre-procedure. 
VE beats remained unchanged during follow-up (Table 4). 
EHRA class improved significantly at both 6 and 12 months 
as compared to pre-RDN (p < 0.01) (Fig. 2).
None of the patients underwent PVI within 1 year follow-
up post-RDN.
No change was found in LV and LA volumes and dimen-
sions at 6- and 12 months post RDN (Supplement, Table S1). 
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QOL improved significantly at both follow-up visits (as 
compared to pre-procedure; +11 ± 15 points at 6 months, 
p < 0.01 and + 10 ± 19 at 12 months, p = 0.04) (Fig. 3).
A total of 3/20 (15%) patients underwent an ECV post 
RDN due to recurrence of AF at 6 months; the average 
period to perform the first ECV post-RDN in these patients 
was 134 ± 83 days. In two out of these three patients a sec-
ond ECV was done and one patient received a total of three 
ECV’s during follow-up.
Despite efforts in maintaining initial drug regimens dur-
ing the course of the study, antiarrhythmic drugs or drug 
dosages were increased in 3/20 patients (these were different 
patients from who underwent an ECV) and decreased in 6/20 
patients. Antihypertensive medication was increased in 2/20 
patients and decreased or stopped in 4/20 patients.
Discussion
This single-center pilot study suggests that RDN was able 
to significantly decrease AF burden in min/day as meas-
ured using an ICM, together with an improvement in QOL. 
Finally, RDN appeared safe with a positive effect on blood 
pressure.
Sympathetic hyperactivity has been considered an impor-
tant source for the induction and maintenance of arrhythmias 
[15]. Previous studies provided evidence for the presence of 
increased atrial sympathetic activity in both persistent and 
paroxysmal AF, suggesting autonomic remodeling may be 
part of the atrial substrate for AF [16, 17].
Pathophysiological studies demonstrated that by modu-
lating the SNS through RDN, AF control might improve 
[18]. Linz and colleagues demonstrated the effect of RDN on 
heart rate and VRR in pigs with permanent AF; the authors 
described a reduction of 24% in VRR in the treated pigs vs. 
sham [19]. Furthermore, the potential effects of RDN on 
ventricular electrophysiological properties should be men-
tioned. Huang and colleagues demonstrated that RDN could 
alter the ventricular effective refractory period (ERP) and 
action potential duration (APD) in eight dogs as compared to 
a sham operation group (N = 8) [20]. The authors described 
a prolongation of ventricular APD after RDN, which hypo-
thetically could prevent the occurrence of fatal ventricular 
arrhythmias (VA). A multicenter registry reported that RDN 
appeared to be safe and efficacious in reducing VA burden 
in patients with chronic heart failure; the procedure was 
performed in patients with a few or no further therapeutic 
options [21]. Finally, successful anecdotal experience was 
Fig. 1  Screening process based 
on inclusion- and exclusion 
criteria. AF atrial fibrillation, 
antiHT antihypertensive medi-
cation, BMI body mass index, 
EHRA European Heart Rhythm 
Association, HT hypertension, 
PVI pulmonary vein isolation
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achieved with RDN in patients with refractory vasospastic-
induced ventricular tachycardia [22]. The findings, however, 
do suggest that RDN might be a potentially more appealing 
option to modify cardiac electrophysiological properties as 
compared to pivotal work on cardiac catheter ablation which 
proved to shorten the ERP and increase the incidence of 
premature ventricular complexes [23]. Of note, in the present 
study, no changes were observed over time in the incidence 
of ventricular ectopic beats.
Several recent randomized sham controlled trials proved 
the blood pressure lowering effect of RDN in both hyperten-
sive patients taken off medication as well as in patients with 
uncontrolled hypertension, respectively [12, 24–26]. The 
multi-electrode EnligHTN™ catheter showed to decrease 
BP based on ABPM and to reduce renal norepinephrine 
in previous animal studies [27, 28]. Specifically related to 
the present human study, similar BP lowering effect was 
observed with the same catheter in patients with treatment-
resistant hypertension [29].
Besides the antihypertensive effects of RDN, an exper-
imental study by Tsai and colleagues showed the anti-
arrhythmic effects of RDN in six ambulatory dogs by 
measuring lower nerve activity at the level of the stel-
late ganglion with also a decrease in paroxysmal atrial 
tachycardia episodes and duration after RDN as compared 
to controls [10]. Moreover, two clinical studies assessed 
the antiarrhythmic effect of RDN in addition to PVI in 
hypertensive patients with symptomatic AF. One of these 
studies demonstrated a positive correlation between the 
decrease in mean BP and the decline in AF burden. A 
reduction of 5–10 mmHg in mean BP led to a 7% decrease 
in mean AF burden as measured with an ICM [30]. Unfor-
tunately, in the present study, we were not able to show a 
clear correlation between the change in blood pressure and 
change in AF burden following RDN. Pokushalov and col-
leagues showed that RDN on top of PVI in patients with 
symptomatic AF and resistant hypertension reduced the 
incidence of AF recurrence rates significantly. At 1 year, 
based on 24 h-holter monitoring, 69% of the patients in 
the PVI + RDN were free of AF episodes, while in the PVI 
only group, only 29% of the patients remained free of AF 
Table 1  Baseline characteristics of the study population
Values are mean ± SD or n (%)
AF atrial fibrillation, BMI body mass index, BP blood pressure, CVA 
cerebrovascular accident, EHRA European Heart Rhythm Associa-
tion, IHD ischemic heart disease, PVI pulmonary vein isolation
a 2/20 patients were intolerant for beta−blockers
Total study population (N = 20)
Age, years 64 ± 7
Male n, (%) 9 (45)
BMI (kg/m2) 30.7 ± 5.6
Paroxysmal AF n, (%) 18 (90)
EHRA class II 15 (75)
EHRA class III 5 (25)
Mean heart rate (bpm) 71 ± 15
Office BP (mmHg) 153 ± 17/88 ± 11
Ambulatory BP (mmHg) 130 ± 15/77 ± 9
Cardiovascular risk factors n, (%)
 Diabetes 2 (10)
 Hypertension 20 (100)
 Dyslipidemia 8 (40)
 Smoking 1 (5)
 Family history of IHD 4 (20)
Cardiovascular history n, (%)
 Prior PVI 4 (20)
 Prior CVA 2 (10)
Antiarrhythmic drugs n, (%)
 Class I 4 (20)
 Class II 1 (5)
 Class III 12 (60)
 Class V 2 (10)
Antihypertensive drugs n, (%)
 ACE-i 7 (35)
 ARB 8 (40)
Beta-blockersa 18 (90)
CCB 10 (50)
Alfa-blocker 3 (15)
Diuretics 13 (65)
Table 2  AF burden on ICM 
monitors pre-RDN vs. 6- and 
12-month follow-up
Values are in median [IQR]
AF atrial fibrillation, ICM implantable cardiac monitor, VRR ventricular rate response during AF
*Between pre-RDN vs. 6 months, **pre-RDN vs. 12 months. Results are based on 18/20 patients, and 
patients with permanent AF were excluded
Pre-RDN 6 months 12 months p* p**
AF episodes (n) 1 (0–11) 1 (0–11) 3 (0–16) 0.84 0.31
Total episodes AF (min) 125 (2–978) 44 (0–2833) 84 (0–544) 0.64 0.03
AF min/day 1.39 (0–10.9) 0.67 (0–31.6) 0.94 (0–6.0) 0.64 0.03
Highest VRR (bpm) 127 (105–145) 117 (104–141) 106 (75–126) 0.09 0.01
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episodes [6]. A dedicated prospective randomized con-
trolled trial is currently ongoing to determine the efficacy 
of RDN on top of PVI in patients with hypertension [31] 
(Clinicaltrials.gov, NCT02115100).
It can be hypothesized that the antiarrhythmic effects of 
RDN could be due to a synergistic effect of (a) better BP 
control (partly) withdrawing an important risk factor for AF 
recurrence and (b) improving AF control by modifying elec-
trophysiological settings like prolongation of the atrial effec-
tive refractory period [3, 32]. AF burden (in min/day and 
episodes) decreased significantly at 1 year follow-up; how-
ever, it did not reach statistical significance at 6 months’ fol-
low-up. Although the latter could be due to the fact that the 
variability in AF burden at 6 months was high, an increas-
ing effect of RDN over time could not be excluded. In the 
recently published SPYRAL-ON MED trial, BP reduction 
was greater at 6 months as compared with 3 months [33].
To the best of our knowledge, the present work is the 
first clinical study to demonstrate that RDN, without con-
comitant PVI, may reduce AF burden as measured using 
an ICM. Measuring AF burden with an ICM is superior to 
intermittent AF event monitoring using 24 h-holters or event 
Table 3  Office and ambulatory 
blood pressure change pre-RDN 
vs. 6- and 12-month follow-up
Values are mean ± SD
ABPM ambulatory blood pressure measurement, BP blood pressure
*Pre−RDN vs. 6 months
**Pre−RDN vs. 12 months
Pre-RDN 6 months 12 months p* p**
Office systolic BP (mmHg) 153 ± 17 148 ± 17 133 ± 16 0.13 < 0.01
Office diastolic BP (mmHg) 89 ± 10 81 ± 11 81 ± 10 0.006 0.007
24 h ABPM systolic (mmHg) 131 ± 16 121 ± 9 124 ± 11 0.007 0.07
24 h ABPM diastolic (mmHg) 78 ± 9 72 ± 6 74 ± 9 0.006 0.16
Table 4  24 h-holter monitoring for (S)VE beats
Values are mean ± SD or are median [IQR]
(S)VE (supraventricular)ectopic beats
*Pre−RDN vs. 6 months
**Pre−RDN vs. 12 months
Pre-RDN 6 months 12 months p* p**
Heart rate 
(bpm)
71 ± 15 66 ± 8 70 ± 12 0.15 0.63
SVE (beats) 187 
(82–948)
137 
(43–1096)
79 (13–763) 0.36 0.05
VE (beats) 35 (3–153) 22 (3–86) 42 (5–134) 0.57 0.73
Fig. 2  Change in EHRA class 
at follow-up visits (6- and 
12 months results). EHRA 
European Heart Rhythm Asso-
ciation, pre-RDN prior to renal 
sympathetic denervation, 6M 6 
months, 12M 12 months
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recorders [34]. Monitoring treatment effect based on symp-
toms alone is unreliable since approximately 50% of AF 
recurrences proved to occur in asymptomatic patients [35]. 
Vice versa, Padeletti and colleagues showed a high intra-
patient burden variability and demonstrated that only 52% 
of patient symptoms appear to be correlated to documented 
AF [36]. The latter was confirmed in our study in which we 
found a clear discrepancy between pre-procedural EHRA 
class and the actual AF episodes as measured using either 
24 h-holter or ICM. Nevertheless, despite a large variability 
in AF burden between patients we were able to demonstrate 
a significant reduction in AF burden post RDN.
Of note, despite their known limitations, the vast major-
ity of previous studies assessing the efficacy of either PVI 
or surgical ablation used intermittent and symptom-based 
monitoring (i.e. 24 h holter monitoring or event monitors) 
to demonstrate their effect [37].
Finally, we were not able to demonstrate any changes in 
echocardiographic parameters and diastolic function in our 
study population, which could be due to either the small 
sample size or advanced stages of LA dilatation prior to 
study participation.
Limitations
Despite the positive results in this present study, there are 
several limitations that should be taken into account. First, 
it concerns a small study cohort (N = 20) in whom two 
patients progressed to permanent AF and were excluded 
from the analysis of AF burden. Second, in approximately 
50% of the treated patients, we stopped or decreased drug 
dosages of antihypertensive and/or anti-arrhythmic drugs. 
Third, adherence to antihypertensive drugs was not meas-
ured and only confirmed by the physician at the outpatient 
clinic visit. Fourth, the ICM used in this study was not able 
to transmit wirelessly the ECG to the office, which could 
have led to an underestimation of the AF events in case of 
data overload and a lack of memory (which occurred in 1/20 
patient). Fifth, RDN was performed with the EnligHTN™ 
ablation catheter which enabled the operator to ablate only 
in the main renal arteries and is currently no longer avail-
able for clinical use. Whether the use of current generation 
devices using different technologies as ultrasound, ethanol or 
RF sidebranch ablation would have resulted in more potent 
results remains to be determined. Finally, since no sham 
control group was included in the present pilot study, the 
potential of a placebo effect cannot be ruled out. Neverthe-
less, we showed the potential value of RDN in patients with 
paroxysmal AF and warrants the conduction of larger and 
sham controlled studies assessing the anti-arrhythmic effect 
of RDN.
Conclusion
This pilot study suggests that RDN was safe and able to 
decrease AF burden in min/day as measured using an ICM at 
12-month follow-up, together with an improvement in QOL 
in patients with symptomatic paroxysmal or persistent AF. 
Large-scale randomized trials are needed to demonstrate the 
value of RDN in hypertensive patients with AF.
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